Upregulation of SNHG3 expression associated with poor prognosis and enhances malignant progression of ovarian cancer

Cancer Biomarkers : Section a of Disease Markers
Lan HongYifeng Wang

Abstract

Aberrant expression of long non-coding RNAs is involved in the progression of ovarian cancer. However, the clinical significance and biological functions of SNHG3 expression was little known in ovarian cancer (OC). The SNHG3 expression in ovarian cancer tissues and paired adjacent normal tissues was detected using quantitative real time polymerase chain reaction (qRT-PCR). Gain-of function and loss-of function assays were performed in ovarian cancer cells to demonstrate the effects of SNHG3 expression on cell proliferation and invasion. The relative protein expression levels were determined using western blot analyses. The expression of SNHG3 was significantly up-regulated in ovarian cancer tissues compared with adjacent normal tissues. Higher SNHG3 expression levels positively associated with FIGO stage, lymph node metastasis, and poor prognosis of ovarian cancer patients. Univariate and multivariate Cox regression analysis implied that FIGO stage, lymph node metastasis, higher SNHG3 expression were independent prognostic factors for overall survival (OS) rate in ovarian cancer patients. Gain-of function and loss-of function assays demonstrated that SNHG3 knockdown inhibited ovarian cancer cell proliferation and invasion abili...Continue Reading

References

Feb 26, 2009·Cell·Chris P PontingWolf Reik
May 11, 2013·British Journal of Cancer·S W CheethamM E Dinger
Jun 25, 2013·Cancer Letters·Xuefei ShiYong Song
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Sep 6, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jing LiXiaoying He
Sep 17, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ting ZhangLi Liu
Jan 21, 2016·Nature Reviews. Clinical Oncology·Steven Narod
Feb 13, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yijun YangWenjun Cheng
May 4, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A Bookman
Jul 26, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Yanan WangXiaojun Zhou

❮ Previous
Next ❯

Citations

Apr 25, 2020·Cancers·Martín Salamini-MontemurriMaría Esperanza Cerdán
Feb 23, 2019·International Journal of Immunopathology and Pharmacology·Jun ChenYong Zhang
Aug 28, 2019·Journal of Cellular Biochemistry·Linqiang PengHongli Xin
Feb 11, 2020·Frontiers in Oncology·Cecilie AbildgaardSilvia R Rogatto
Aug 28, 2020·OncoTargets and Therapy·Yuan QinHao Zhang
Dec 10, 2020·Cancer Cell International·Bin XuJunfei Shao
May 26, 2021·Technology in Cancer Research & Treatment·Yongqun LiJiguang Meng
Jun 23, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Alexey V ZamaraevBoris Zhivotovsky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adherens Junctions

An adherens junction is defined as a cell junction whose cytoplasmic face is linked to the actin cytoskeleton. They can appear as bands encircling the cell (zonula adherens) or as spots of attachment to the extracellular matrix (adhesion plaques). Adherens junctions uniquely disassemble in uterine epithelial cells to allow the blastocyst to penetrate between epithelial cells. Discover the latest research on adherens junctions here.

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.